Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populationsArticle Published on 2022-09-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 진단, [키워드] Advax-CpG adverse event antibody Cellular immune response composed conducted COVID-19 COVID-19 vaccine dose double-blind fatigue geometric mean concentration humoral incidence injection site pain Mild outcome participant phase Phase 2 phase 2 trial Placebo placebo-controlled Population primary immunogenicity Protein Randomized randomized placebo-controlled trial receive Safety safety profile SARS-CoV-2 SARS-CoV-2 spike protein second dose Serious Adverse Event Seroconversion seroconversion rate seronegative seropositive SpikoGen subunit subunit protein vaccine the placebo group vaccination Vaccine Volunteer were recorded [DOI] 10.1016/j.cmi.2022.04.004 PMC 바로가기
Is IFN expression by NK cells a hallmark of severe COVID-19?Research article Published on 2022-09-012022-10-05 Journal: Cytokine [Category] 변종, 치료기술, 치료제, [키워드] addition CD107a clinical form contribute CoV COVID-19 cytolytic cytotoxic activity Cytotoxic granules decrease Defense disease elicited Express expression form Frequency Granule granzyme B groups hallmark Host IFN IFN-α IFN-γ immune responses immune system individual Innate immunity interferons involved Ki-67 Killer cell mechanism Mild natural Natural killers NK cell NK cells pathogenesis of COVID-19 PBMC PBMCs peptide pool profile question recovered COVID-19 patient reduced SARS-CoV-2 severe COVID-19 severity significant increase spike the disease the healthy viruses Volunteer [DOI] 10.1016/j.cyto.2022.155971 [Article Type] Research article
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in ChileArticle Published on 2022-08-242022-11-15 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료기술, [키워드] activate acute respiratory syndrome Adverse reaction age analyzed binding domain blood sample cellular characterized Chilean circulating clinical trial CoronaVac coronavirus coronavirus 2 coronavirus disease COVID-19 dose effective vaccine enrolled healthy humoral IFN-γ IgG immunogenicity Immunoglobulin inactivated incidence induce injection interferon-γ Local measure Mild neutralizing antibody neutralizing capacity Pain peptide Phase 3 phase 3 clinical trial Placebo pool profiles promote Randomly RBD Registered reported respiratory Safe Safety SARS-CoV-2 SARS-CoV-2 antigens second dose secretion separated severe adverse event significant increase subset T cells T-cell Response the vaccine Vaccine Vaccines Volunteer volunteers was performed [DOI] 10.1093/cid/ciab823 PMC 바로가기
Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 PandemicRandomized Controlled Trial Published on 2022-08-242022-10-04 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, [키워드] 1.26 acute respiratory syndrome adverse events Against age Antibody Response Antibody titer assigned BCG BCG vaccination cellular clinical confidence interval control group coronavirus coronavirus disease COVID-19 COVID-19 infection cumulative cytokine response death diagnosed with COVID-19 end point EU Clinical Trial Follow-up Frequency groups had no hazard ratio Heterologous humoral immune responses Immunity incidence incidence of COVID-19 individuals Infection Influenza intracutaneous medical intervention multicenter Older Patient Placebo placebo-controlled trial polymerase chain positive primary end point Randomly required respiratory respiratory infections respiratory tract infection SARS-CoV-2 SARS-COV-2 infection secondary severity significantly stimulated subdistribution tested tract trained immunity Trial Tuberculosis vaccination Vaccine Volunteer volunteers [DOI] 10.1093/cid/ciac182 PMC 바로가기 [Article Type] Randomized Controlled Trial
A validated LC-MS/MS method for determination of antiviral prodrug molnupiravir in human plasma and its application for a pharmacokinetic modeling study in healthy Egyptian volunteers인간 혈장에서 항 바이러스 전구 약물 Molnupiravir의 결정을위한 검증 된 LC-MS/MS 방법 및 건강한 이집트 자원 봉사자들의 약동학 적 모델링 연구에 대한 적용Article Published on 2022-08-152022-08-31 Journal: Journal of chromatography. B, Analytical technolog [Category] COVID19(2023년), MERS, SARS, 치료기술, 치료제, [키워드] acetic acetic acid acetonitrile Agilent analyte analyzed Antiviral approach AUC C max Concentration confidence interval detection determine develop dosage dose Eclipse Efficacy ESI evaluate extraction FDA flow rate geometric mean geometric mean ratios Geometric means GMR Guidance healthy healthy volunteer healthy volunteers Human plasma LC-MS/MS Linear regression linearity m/z mass spectrometer mass spectrometry maximum concentration metabolite mixture molnupiravir N-hydroxycytidine NHC pharmacokinetic pharmacokinetic data plasma Population Population Pharmacokinetic Modeling positive protein precipitation pumped recommendation required ribavirin SARS-CoV-2 Simulation solvent subjects therapeutic target therapeutic targets Treatment triple quadrupole mass spectrometer United State United States Volunteer was performed was used were used [DOI] 10.1016/j.jchromb.2022.123363 PMC 바로가기 [Article Type] Article
Drivers of avian habitat use and detection of backyard birds in the Pacific Northwest during COVID-19 pandemic lockdowns Research Published on 2022-08-112022-10-05 Journal: Scientific Reports [Category] 치료기술, [키워드] affected analyzed Bird changes in Community COVID-19 pandemic driver Effect exhibited Human initial intensity Local lockdown lockdown restriction lockdowns platform reduced response stressors Support unique Volunteer [DOI] 10.1038/s41598-022-16406-w [Article Type] Research
Plant formulation ATRICOV 452 in improving the level of COVID-19 specific inflammatory markers in patientsResearch article Published on 2022-08-012022-10-05 Journal: Contemporary Clinical Trials Communications [Category] 바이오마커, 신약개발, 임상, [키워드] adverse event assigned Care clinical trial conducted COVID-19 COVID-19 patient CTRI determine dose dropped effective Efficacy evaluate faster Frequency healthcare healthy healthy volunteer hospital Human Importance IMPROVE Inflammatory marker inflammatory markers objective organ system oxygen Patient phase Phase 1 Phase 2 phase 2 trial Placebo plant Plant formulation (ATRICOV 452) primary analysis population randomization receive reduce Registration Result Safe setting Standard of care Support therapeutic intervention Tolerability treatment group Trial Volunteer [DOI] 10.1016/j.conctc.2022.100961 [Article Type] Research article
A multidisciplinary effort to increase COVID-19 vaccination among the older adults노년층의 코로나19 예방접종 확대를 위한 다학제적 노력Article Published on 2022-08-012022-09-11 Journal: Frontiers in Public Health [Category] 변종, [키워드] addressed Adults adverse effect analyzed approach case study clinics Cluster Community COVE COVID-19 COVID-19 vaccination COVID-19 vaccine Data analysis dose effort elderly expressed facilitated healthcare worker Healthcare workers implementation information initiated Intention morbidity and mortality multidisciplinary team Older older adult Phase 1 Phase I primary care reduce reported risk of infection significantly Singapore SMS the vaccine vaccinate vaccination vaccination appointment vaccination appointments Vaccination program Vaccine Vaccine hesitancy vaccine promotion variants of concern Volunteer [DOI] 10.3389/fpubh.2022.904161 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trialCOVID-19 회복기 참가자에 대한 FINLAY-FR-1A 백신의 안전성 및 면역원성: 공개 라벨 2a상 및 이중 맹검, 무작위 배정, 위약 대조, 2b상, 심리스, 임상 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adverse event All participants Alpha anti-RBD antibody assigned Asymptomatic Beta clinical clinical trial clinical trials Complete control group control groups convalescent convalescent individual convalescent individuals COVID-19 criteria Cuba defined delta variant Delta variants dimeric double-blind education elicited ELISA Endpoint enrolled Environment evaluate evaluated experimental group first stage geometric mean geometric mean titre geometric mean titres greater hematology ICTRP IgG antibodies immune response immunogenicity immunology increase in injected injection injection site Intervention intervention group Mild minor Moderate COVID-19 natural immunity Negative PCR neutralisation test neutralising antibody Occurrence Open-label Pain participant Participants PCR test per-protocol population Phase 1 Phase 2 Placebo placebo group placebo-controlled prevaccination Primary outcome Primary outcomes Public randomised Randomly Receptor binding domain recruited Registered registry reported Safety safety analysis safety population safety profile SARS-CoV-2 Science seamless secondary Secondary endpoints Serious Adverse Event Serious Adverse Events seroconversion rate sexual single dose stages study population technology the placebo group titre Trial two groups vaccination Vaccine vaccine immunogenicity Virus neutralisation Volunteer was done WHO-ICTRP [DOI] 10.1016/S2213-2600(22)00100-X PMC 바로가기 [Article Type] Clinical Trial
Prevalence of saliva immunoglobulin A antibodies reactive with severe acute respiratory syndrome coronavirus 2 among Japanese people unexposed to the virus바이러스에 노출되지 않은 일본인 중 중증급성호흡기증후군 코로나바이러스 2에 반응하는 타액 면역글로불린 A 항체의 유병률Article Published on 2022-08-012022-09-12 Journal: Microbiology and immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% confidence interval acute respiratory syndrome age antibodies antibody blood sample caused collected conducted coronavirus COVID-19 COVID-19 pandemic COVID-19-related death enzyme-linked immunosorbent expected explain healthy IgA IgA antibodies IgA antibody Immunoglobulin immunoglobulin A incidence individual investigated Japan Japanese Japanese people Occurrence participant participated positive Prevalence Protein public health reactive Receptor binding domain Saliva saliva IgA saliva sample SARS-CoV-2 secretory IgA secretory immunoglobulin A Seroprevalence serum subunit the antibody the SARS-CoV-2 virus virus infection Volunteer while [DOI] 10.1111/1348-0421.13011 PMC 바로가기 [Article Type] Article